Plasminogen activator proteins tested as prognostic markers.
Nelson
N J
NJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005858:Germany; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D016017:Odds Ratio; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D015842:Serine Proteinase Inhibitors / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D003520:Cyclophosphamide; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D005472:Fluorouracil; D008727:Methotrexate